Daver NG, Zeidan AM, Stein AS, Zeidner JF, et al. Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPalpha-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia. Cancer 2026;132:e70626.
PMID: 42829896